CN116421517B - Skin anti-aging composition and application and skin care product thereof - Google Patents
Skin anti-aging composition and application and skin care product thereof Download PDFInfo
- Publication number
- CN116421517B CN116421517B CN202310385567.4A CN202310385567A CN116421517B CN 116421517 B CN116421517 B CN 116421517B CN 202310385567 A CN202310385567 A CN 202310385567A CN 116421517 B CN116421517 B CN 116421517B
- Authority
- CN
- China
- Prior art keywords
- phase
- skin
- skin care
- care product
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 56
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 claims abstract description 34
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 claims abstract description 34
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 claims abstract description 34
- 229940117895 bakuchiol Drugs 0.000 claims abstract description 34
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 33
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims abstract description 23
- 239000009606 Bidens pilosa plant extract Substances 0.000 claims abstract description 22
- 241000219823 Medicago Species 0.000 claims abstract description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 27
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 18
- -1 PEG-100 stearate Chemical compound 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- 229940049964 oleate Drugs 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 8
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 6
- 240000007817 Olea europaea Species 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 229940104261 taurate Drugs 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 229960003237 betaine Drugs 0.000 claims description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 5
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 5
- 229940075529 glyceryl stearate Drugs 0.000 claims description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 5
- 229940100460 peg-100 stearate Drugs 0.000 claims description 5
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 5
- LWBVAHQZGAKXPU-BOXHHOBZSA-M sodium;(4s)-4-amino-5-octadecoxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)[C@@H](N)CCC([O-])=O LWBVAHQZGAKXPU-BOXHHOBZSA-M 0.000 claims description 5
- 229940032094 squalane Drugs 0.000 claims description 5
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 5
- 230000001815 facial effect Effects 0.000 claims description 4
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- QBQSKYIIEGLPJT-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.OCCOC(=O)C=C QBQSKYIIEGLPJT-UHFFFAOYSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- UUMJPBCXZURUCJ-UHFFFAOYSA-N 4-octanoyloxy-4-oxobutanoic acid Chemical compound CCCCCCCC(=O)OC(=O)CCC(O)=O UUMJPBCXZURUCJ-UHFFFAOYSA-N 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 235000001553 Betula platyphylla Nutrition 0.000 claims description 3
- 241001313086 Betula platyphylla Species 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229920006037 cross link polymer Polymers 0.000 claims description 3
- 229940008099 dimethicone Drugs 0.000 claims description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 229940080313 sodium starch Drugs 0.000 claims description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000281 trometamol Drugs 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 27
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 21
- 229940045997 vitamin a Drugs 0.000 abstract description 17
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 14
- 235000019155 vitamin A Nutrition 0.000 abstract description 14
- 239000011719 vitamin A Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 230000033228 biological regulation Effects 0.000 abstract description 11
- 230000037394 skin elasticity Effects 0.000 abstract description 11
- 210000002950 fibroblast Anatomy 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 230000037303 wrinkles Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 69
- 239000000047 product Substances 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000003702 retinoic acid receptors Human genes 0.000 description 8
- 108090000064 retinoic acid receptors Proteins 0.000 description 8
- 229960003471 retinol Drugs 0.000 description 8
- 239000011607 retinol Substances 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 206010040954 Skin wrinkling Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 235000020944 retinol Nutrition 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 6
- 230000037393 skin firmness Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 240000004658 Medicago sativa Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- 102100036407 Thioredoxin Human genes 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 3
- 229930003658 monoterpene Natural products 0.000 description 3
- 235000002577 monoterpenes Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102100026608 Aldehyde dehydrogenase family 3 member A2 Human genes 0.000 description 2
- 244000104272 Bidens pilosa Species 0.000 description 2
- 235000010662 Bidens pilosa Nutrition 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102100029425 Hyaluronan synthase 3 Human genes 0.000 description 2
- 101710197055 Hyaluronan synthase 3 Proteins 0.000 description 2
- 102000012334 Integrin beta4 Human genes 0.000 description 2
- 108010022238 Integrin beta4 Proteins 0.000 description 2
- 108010058996 Long-chain-aldehyde dehydrogenase Proteins 0.000 description 2
- 102100022941 Retinol-binding protein 1 Human genes 0.000 description 2
- 108050008744 Retinol-binding protein 1 Proteins 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000014823 calbindin Human genes 0.000 description 2
- 108060001061 calbindin Proteins 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 101710192778 Antichymotrypsin-1 Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 102000016947 Chemokine CXCL6 Human genes 0.000 description 1
- 108010014423 Chemokine CXCL6 Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 description 1
- 101710194435 Dehydrogenase/reductase SDR family member 9 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 102000044465 Galectin-7 Human genes 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 1
- 101100537088 Homo sapiens TXN gene Proteins 0.000 description 1
- 102000007005 Interleukin-1 Type II Receptors Human genes 0.000 description 1
- 108010008144 Interleukin-1 Type II Receptors Proteins 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010046750 Urticaria papular Diseases 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000008664 papular urticaria Diseases 0.000 description 1
- 108010012038 peptide 78 Proteins 0.000 description 1
- 229940125863 peptide 78 Drugs 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001403 relative X-ray reflectometry Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 125000002523 retinol group Chemical group 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
A skin anti-aging composition and application and skin care products thereof belong to the technical field of skin care products. Consists of the following substances: 5 to 30 parts of bakuchiol, 20 to 60 parts of bidens pilosa extract and 25 to 75 parts of alfalfa extract. The skin anti-aging composition and the application and the skin care product thereof are that the skin care product prepared by the composition is milder than the vitamin A product which is smeared on the skin of a human body; the three active components are compounded, so that the synergistic effect is achieved, all important skin regulation and control functions of vitamin A can be well simulated, the activity of fibroblasts is enhanced, and the proliferation of the fibroblasts and the function of synthesizing skin beneficial components are obviously improved; the prepared skin care product can obviously reduce skin wrinkles, smooth skin and increase skin elasticity.
Description
Technical Field
The invention belongs to the technical field of skin care products, and particularly relates to a skin anti-aging composition and application thereof, and a skin care product.
Background
With the research development of skin care product science and the increasing demands of consumers on the efficacy of skin care products, anti-aging skin care becomes one of the most important consumer appeal. Research shows that the skin gradually enters a natural aging state from 20 to 25 years old, and the aging speed is different according to the genetic genes and living habits of each person. Due to the influence of factors such as fast-paced life, stay up, working pressure and the like, the primary and old appearance of skin of a part of young consumers aged 20 years is obvious, including dry and tight skin; facial relaxation sags slightly; fine lines appear on eyes; neck lines appear; slow recovery after tanning, etc. The anti-aging is to make various anti-aging works in the early stage of skin aging and delay the aging speed.
Human skin is composed of epidermis, basement membrane and dermis, and the actions of fibroblasts located in dermis include production of collagen, elastin, and dextran, etc., which have the actions of maintaining skin elasticity, dermis moisturizing, etc. The activity of fibroblasts plays a vital role in maintaining a healthy appearance of the skin. It has been observed that with age, the proliferation of fibroblasts and the function of synthesizing skin benefit ingredients gradually decrease.
Vitamin A is a very classical skin care ingredient which acts on the epidermis of the skin, promotes cell proliferation, maintains normal circulation of the skin, repairs lost collagen, reduces signs of wrinkles and premature aging (such as abnormal pigmentation, rough spots and dry skin), and has the effects of removing wrinkles and resisting photoaging. Vitamin a does not refer to a single chemical substance, but includes retinol (retinol, a alcohol), retinaldehyde (a aldehyde), retinoic acid (a acid), collectively referred to as Retinoids (Retinoids). However, there are different levels of irritation, whether acids, aldehydes, ketones, alcohols, or esters, and consumers experience discomforts such as molting, redness, stinging during use.
Thus, finding a safer, non-irritating ingredient to combat skin that has similar efficacy to vitamin a is an increasing concern for researchers in this field. As a result of the efforts of researchers in this field, many plant-derived, retinoid components have been discovered which are characterized as mild. They can in some ways even exceed the retinoids in terms of skin anti-aging ability, but none of the ingredients can mimic the effects of vitamin a in all directions.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to design and provide a skin anti-aging composition, application thereof and a technical scheme of skin care products, wherein three active components of the composition are compounded, have a synergistic effect, and can well simulate all important skin regulation and control functions of vitamin A; the prepared skin care product is mild, safe and non-irritating, and can remarkably reduce skin wrinkles, smooth skin and increase skin elasticity.
The anti-aging composition is characterized by comprising the following substances in parts by weight: 5 to 30 parts of bakuchiol, 20 to 60 parts of bidens pilosa extract and 25 to 75 parts of alfalfa extract.
The anti-aging composition is characterized by comprising 10-25 parts of bakuchiol, 30-50 parts of bidens pilosa extract and 30-65 parts of alfalfa extract.
The anti-aging composition is characterized by 16-20 parts of bakuchiol, 35-45 parts of bidens pilosa extract and 40-50 parts of alfalfa extract.
The application of the anti-aging composition in preparing skin care products.
The application of the anti-aging composition in preparing the skin care product is characterized in that the skin care product is water aqua, emulsion, cream, essence, facial mask or gel, and the addition amount of the composition is 0.5-10%, preferably 2-8%, more preferably 4-6% of the total mass of the skin care product.
The skin care product prepared from the anti-aging composition is characterized by comprising the composition and an auxiliary agent, wherein the auxiliary agent is at least one of a chelating agent, a thickening agent, a humectant, a solubilizer, an emulsifying agent, a pH regulator, a preservative, a solvent, a skin feel improver, grease and essence.
The skin care product prepared from the anti-aging composition is characterized in that:
the chelating agent is disodium EDTA and/or tetrasodium EDTA;
the thickener is at least one of carbomer, sodium polyacrylate, xanthan gum, acrylic acid (ester) copolymer sodium, acrylamide dimethyl taurate/VP copolymer, acrylic acid (ester) C10-30 alkanol acrylate cross-linked polymer, polyacrylate cross-linked polymer-6 and acrylic acid hydroxyethyl acrylate/sodium acryl dimethyl taurate copolymer;
the humectant is at least one of glycerol, propylene glycol, 1, 3-propylene glycol, butanediol, trehalose, dipropylene glycol, 1, 2-pentanediol, betaine and 1, 2-hexanediol;
the solubilizer is PEG-40 hydrogenated castor oil;
the emulsifier is at least one of cetostearyl oleate/sorbitan olive oleate, PEG-100 stearate, glyceryl stearate, lecithin, tween 60 and sodium stearyl glutamate;
the pH regulator is at least one of aminomethylpropanol, sodium hydroxide, arginine, citric acid, sodium citrate and tromethamine;
the preservative is at least one of phenoxyethanol, p-hydroxyacetophenone, potassium sorbate, sodium benzoate, octyl glycol and ethylhexyl glycerol;
the oil is at least one of squalane, BAIHUA oil, oleum Olivarum, caprylic/capric triglyceride, cetyl ethyl caproate, polydimethylsiloxane, and cetostearyl alcohol;
the skin feel improver is at least one of silica, corn starch and sodium starch octanoyl succinate;
the essence is daily essence;
the solvent is water.
The skin care product prepared from the anti-aging composition is characterized by being an anti-aging essence and comprising a phase A, a phase B and a phase C in percentage by weight;
phase A: 5% of glycerol, 0.8% of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 2% of dipropylene glycol, 0.5% of p-hydroxyacetophenone, 0.5% of 1, 2-hexanediol and the balance of water;
and B phase: 5% caprylic/capric triglyceride, 2% bakuchiol, 4% Bidens pilosa extract, 0.2% tween 60;
and C phase: 4% alfalfa extract;
the preparation method comprises the following steps: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, starting homogenizer, homogenizing at 5000-6000rpm for 4-6min; cooling to below 40deg.C, adding phase C, and stirring.
The skin care product prepared from the anti-aging composition is characterized by being anti-aging emulsion and comprising phase A, phase B and phase C in percentage by weight;
phase A: 5% of glycerol, 0.6% of polyacrylate crosslinked polymer-6, 5% of butanediol, 0.3% of sodium stearyl glutamate, 0.5% of p-hydroxyacetophenone, 0.5% of 1, 2-hexanediol and the balance of water;
and B phase: 6% cetyl ethyl hexanoate, 0.45% bakuchiol, 2% dimethicone, 1.8% Bidens pilosa extract, 1% PEG-100 stearate & glyceryl stearate;
and C phase: 0.75% alfalfa extract;
the preparation method comprises the following steps: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, starting homogenizer, homogenizing at 5000-6000rpm for 5-10min; cooling to below 40deg.C, adding phase C, and stirring.
The skin care product prepared from the anti-aging composition is characterized by being anti-aging cream and comprising A phase, B phase and C phase in percentage by weight;
phase A: 5% of glycerol, 0.5% of sodium polyacrylate, 5% of butanediol, 2% of betaine, 0.5% of p-hydroxyacetophenone, 0.5% of 1, 2-hexanediol and the balance of water;
and B phase: 3% cetyl ethylhexanoate, 3% cetostearyl alcohol, 3% squalane, 0.6% bakuchiol, 2% polydimethylsiloxane, 0.4% bidens pilosa extract, 3% cetylstearyl olive oleate/sorbitan olive oleate;
and C phase: 1% alfalfa extract;
the preparation method comprises the following steps: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, starting homogenizer, homogenizing at 5000-6000rpm for 5-10min; cooling to below 40deg.C, adding phase C, and stirring.
The purity of the bakuchiol is more than or equal to 99 percent (tested by an HPLC method), and the bakuchiol can be directly purchased from the market.
The Bidens pilosa extract has the commodity name: revinage (Rawei internal treatment), manufacturer: brazil chemyupon (chemical alliance).
The alfalfa extract has the commodity name: VITANOL (vitamin), manufacturer: france Silab (alizarin blogs).
Alfalfa, the stems and leaves of which are rich in proteins, minerals, multivitamins and carotenes, and coumarin derivatives. The alfalfa extract is rich in galactomannans, like vitamin A, and can regulate metabolism of epidermis and increase synthesis of protein and silk polymerized protein serving as keratinocyte differentiation markers. Cell turnover is also improved in the absence of nutrients and calcium mediators, collagen I synthesis is stimulated, and extracellular matrix protection is achieved by inhibition of metalloproteinases that cause degradation of elastin.
The fructus Psoraleae has main chemical components of monoterpene phenol, monoterpene phenol dimer, heterodimer of monoterpene phenol and flavone, chalcone, coumarin and isoflavone, flavone, coumarin and fatty acid, etc. High purity bakuchiol extracted from fructus Psoraleae can promote proliferation of ESF-1 cells, promote expression of collagen and matrix metalloproteinase inhibitor mRNA, and inhibit expression of matrix metalloproteinase mRNA, thereby exerting skin aging resisting effect.
Bidens pilosa is whole herb of Bidens pilosa L. Is a Chinese medicine with the functions of detoxicating, detumescence, clearing heat, easing pain, promoting blood circulation, removing blood stasis, regulating qi and removing food retention. The invention adopts the Bidens pilosa extract from Brazil, is rich in long-chain unsaturated diterpenoid compounds with biological activity, can inhibit cell aging, and obviously improves skin texture and fine lines.
The skin anti-aging composition and the application and the skin care product thereof are that the skin care product prepared by the composition is milder than the vitamin A product which is smeared on the skin of a human body; the three active components are compounded, so that the synergistic effect is achieved, all important skin regulation and control functions of vitamin A can be well simulated, the activity of fibroblasts is enhanced, and the proliferation of the fibroblasts and the function of synthesizing skin beneficial components are obviously improved; the prepared skin care product can obviously reduce skin wrinkles, smooth skin and increase skin elasticity.
Detailed Description
The technical scheme of the present invention will be clearly and completely described in the following in connection with the embodiments of the present invention,
it will be apparent that the described embodiments are only some, but not all, embodiments of the invention.
The embodiments described below are exemplary and intended to be illustrative of the invention and should not be construed as limiting the invention
And are clearly limiting.
Example 1: an antiaging composition comprises bakuchiol 6 parts, herba Bidentis Bipinnatae extract 24 parts, and herba Medicaginis extract 70 parts.
Example 2: an antiaging composition comprises bakuchiol 5 parts, herba Bidentis Bipinnatae extract 20 parts, and herba Medicaginis extract 75 parts.
Example 3: an antiaging composition comprises bakuchiol 15 parts, herba Bidentis Bipinnatae extract 60 parts, and herba Medicaginis extract 25 parts.
Example 4: an antiaging composition comprises bakuchiol 20 parts, herba Bidentis Bipinnatae extract 40 parts, and herba Medicaginis extract 40 parts.
Example 5: an antiaging composition comprises bakuchiol 30 parts, herba Bidentis Bipinnatae extract 20 parts, and herba Medicaginis extract 50 parts.
The three components of bakuchiol, bidens pilosa extract and alfalfa extract have targets similar to the vitamin A on the skin, but can not be completely simulated. The alfalfa extract has high coincidence degree with vitamin A in the aspect of epidermal cell gene regulation, but does not influence the gene expression of vitamin A receptor (CRBP 1, CRBP 2), and bakuchiol has regulation and control effects on the two genes. In addition, bakuchiol provides similar activity to retinoids in terms of retinol binding and metabolic genes. However, alfalfa extract and bakuchiol have no regulatory effect on both the RARs and RXRs receptors. Whereas Bidens pilosa extract has a regulatory effect on both receptors. Table 1 shows important regulation targets of vitamin A on skin, and the regulation capacities of different components on different targets are shown in Table 1.
TABLE 1 Regulation ability of different Components on different targets
Target name | Retinoids | Alfalfa extract | Bakuchiol | Bidens pilosa extract |
Papular urticaria antigen 1 (BPAG 1) | - | - | ||
Cytokeratin 10 | - | - | ||
Galectin-7 | - | - | ||
Mitochondrial genome | - | - | ||
Fatty aldehyde dehydrogenase (FALDH) | - | - | ||
Thioredoxin (TRDX; TXN) | - | - | ||
Thioredoxin peroxidase 2 (TDPX 2) | - | - | ||
Superoxide dismutase 1 | - | - | ||
S100 calbindin A4 | - | - | ||
S100 calbindins A8, A9, A7 | + | + | ||
Neutrophil activating peptide 78 (ENA 78) derived from epithelial cells | + | + | ||
Granulocyte chemotactic protein 2 (GCP 2) | + | + | ||
With heparinBound EGF growth factor (HB-EGF) | + | + | ||
Platelet-derived growth factor A subunit (PDGFA) | + | + | ||
Antichymotrypsin 1 (AACT; ACT) | + | + | ||
Hyaluronate synthase 3 (HAS-3) | + | + | + | |
Elastin | + | + | ||
Interleukin 1 receptor type II (IL 1R 2) | + | + | + | |
Cell retinol connexin I | + | Ο | + | |
Tazarotene induction gene 1 (TIG 1) | + | + | ||
Dehydrogenase/reductase SDR family member 9 precursor (DHRS 9) | + | + | ||
Lecithin-retinol acylate transferase (LRAT) | + | + | ||
Cytochrome P450 s | + | + | ||
Collagen I | + | + | + | + |
Collagen IV | + | + | + | |
Integrin beta 4, beta 6 (Integrin beta 4, beta 6) | + | + | ||
Laminin | + | + | ||
Retinoic acid X receptors (Retinoid X receptors, RXRs) | + | Ο | Ο | + |
Retinoic acid receptors (retinoic acid receptors, RARs) | + | Ο | Ο | - |
Note that: "+" indicates positive regulation, "-" indicates negative regulation, and "O" indicates no regulation, and blank indicates no mention.
The results in table 1 show that: by comparing the regulation and control capability of bakuchiol, bidens pilosa extract and alfalfa extract on different targets, the combination and collocation of the three active ingredients can well simulate all important skin regulation and control functions of vitamin A (except RARs receptor). And the increased expression of RAR receptor is the main cause of redness, desquamation and fever of skin when using vitamin A products. Vitamin A can stimulate the increase of RAR receptor expression, and the combination and collocation of the three active ingredients can not stimulate the increase of RAR receptor expression, but can inhibit the expression to a certain extent, thereby reducing the occurrence of the phenomena of redness, desquamation and fever of skin. In addition, the bakuchiol has strong oxidation resistance, and the oxidation resistance of the other two components is improved by matching the bakuchiol, the bakuchiol and the bakuchiol together. In addition, the bakuchiol and the Bidens pilosa extract are both oily and sticky, and the alfalfa extract is a water-soluble extract, so that the use amount of the bakuchiol and the Bidens pilosa extract is correspondingly reduced by matching, and the sticky feel of the final product is reduced.
The anti-aging composition is applied to the preparation of skin care products, wherein the skin care products are water aqua, emulsion, cream, essence, facial mask or gel, and the addition amount of the composition is 0.5-10% of the total mass of the skin care products, preferably 2-8%, and more preferably 4-6%. The auxiliary agent is at least one of chelating agent, thickener, humectant, solubilizer, emulsifier, pH regulator, antiseptic, solvent, skin feel improver, oil and essence. The chelating agent is disodium EDTA and/or tetrasodium EDTA; the thickener is at least one of carbomer, sodium polyacrylate, xanthan gum, acrylic acid (ester) copolymer sodium, acrylamide dimethyl taurate/VP copolymer, acrylic acid (ester) C10-30 alkanol acrylate cross-linked polymer, polyacrylate cross-linked polymer-6 and acrylic acid hydroxyethyl acrylate/sodium acryl dimethyl taurate copolymer; the humectant is at least one of glycerol, propylene glycol, 1, 3-propylene glycol, butanediol, trehalose, dipropylene glycol, 1, 2-pentanediol, betaine and 1, 2-hexanediol; the solubilizer is PEG-40 hydrogenated castor oil; the emulsifier is at least one of cetostearyl oleate/sorbitan olive oleate, PEG-100 stearate, glyceryl stearate, lecithin, tween 60 and sodium stearyl glutamate; the pH regulator is at least one of aminomethylpropanol, sodium hydroxide, arginine, citric acid, sodium citrate and tromethamine; the preservative is at least one of phenoxyethanol, p-hydroxyacetophenone, potassium sorbate, sodium benzoate, octyl glycol and ethylhexyl glycerol; the oil is at least one of squalane, BAIHUA oil, oleum Olivarum, caprylic/capric triglyceride, cetyl ethyl caproate, polydimethylsiloxane, and cetostearyl alcohol; the skin feel improver is at least one of silica, corn starch and sodium starch octanoyl succinate; the essence is daily essence; the solvent is water.
Example 6: an anti-aging essence is added with 10% of example 4 and is prepared from the following components:
example 6 was prepared using the following procedure: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, starting homogenizer, homogenizing at 5000-6000rpm for 4-6min; cooling to below 40deg.C, adding phase C, and stirring.
In the above embodiment 6, the addition amount of the anti-aging composition is any content of 0.5-10% of the total mass of the skin care product, and the anti-aging composition may also include, but is not limited to, any mixture ratio of the embodiments 1-3 and 5, so as to achieve the skin care effect of the present invention.
Example 7: an anti-aging emulsion, added with 3% of example 3, is prepared from the following components:
example 7 was prepared using the following procedure: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, homogenizing at 5000-6000rpm for 5-10min; cooling to below 40deg.C, adding phase C, and stirring.
In the above embodiment 7, the addition amount of the anti-aging composition is any content of 0.5-10% of the total mass of the skin care product, and the anti-aging composition may also comprise, but is not limited to, any proportion of the embodiments 1-5, so as to achieve the skin care effect of the present invention.
Example 8: an anti-aging cream, added with 2% of example 5, is prepared from the following components:
example 8 was prepared using the following procedure: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, homogenizing at 5000-6000rpm for 5-10min; cooling to below 40deg.C, adding phase C, and stirring.
In the above embodiment 8, the addition amount of the anti-aging composition is any content of 0.5-10% of the total mass of the skin care product, and the anti-aging composition may also comprise, but is not limited to, any proportion of the embodiments 1-5, so as to achieve the skin care effect of the present invention.
The composition provided by the invention has the advantages of milder effect, good skin aging resistance and the like, which are further proved by corresponding experimental data.
Experiment 1: the compositions were tested for mildness by comparison, as shown in Table 2.
60 Chinese healthy female subjects were selected, with an age ranging from 20-30 years, with an average age of 26.3.+ -. 3.5 years. The random groups were divided into 2 groups, the first group using an emulsion containing 0.3% retinol, the second group using the emulsion of example 6, used at night daily for 3 consecutive days, and then the skin condition after use was evaluated.
Table 2 consumer evaluation after skin application
Symptoms appear | Using retinol groups | Use of example 6 group |
Reddening and skinning | 50% | 0 |
Acne-breaking | 40% | 0 |
Fever and stinging pain | 16.7% | 0 |
No uncomfortable feeling is generated | 0 | 100% |
Note that: the appearance symptoms are multiple choice questions.
As can be seen from table 2: the essence prepared by the composition has no uncomfortable feeling in the use process. In contrast, the control group using 0.3% retinol showed all skin discomfort, different symptoms in different proportions, and some subjects even showed more than one skin problem. It follows that the skin care products containing the composition are much milder to the consumer than retinol.
Experiment 2: fibroblast activity promoting effect is shown in tables 3-4.
The combination of the three actives in the anti-aging compositions of the present invention resulted in comparative examples 1-6 and inventive example 4 for cell experiments.
TABLE 3 random combinations of actives for different samples
Sample numbering | Bakuchiol (parts) | Bidens pilosa extract (parts) | Alfalfa extract (parts) |
Example 4 | 20 | 40 | 40 |
Comparative example 1 | 20 | - | - |
Comparative example 2 | - | 40 | - |
Comparative example 3 | - | - | 40 |
Comparative example 4 | 20 | 40 | - |
Comparative example 5 | 20 | - | 40 |
Comparative example 6 | - | 40 | 40 |
Note that: "-" means that the ingredient was not added
Table 4I type collagen content determination table
Sample name | Type I collagen synthesis was increased (%) |
NT | - |
Positive control (100 ng/ml TGF-. Beta.1) | 20.49 |
Example 4 | 38.91 |
Comparative example 1 | 17.91 |
Comparative example 2 | 18.23 |
Comparative example 3 | 15.11 |
Comparative example 4 | 20.32 |
Comparative example 5 | 23.26 |
Comparative example 6 | 21.83 |
As can be seen from Table 4, the amounts of bakuchiol, bidens pilosa extract, and alfalfa extract, respectively, increased by 17.91%, 18.23%, and 15.11% for type I collagen synthesis. And the corresponding increase of type I collagen synthesis is 20.32%, 23.26% and 21.83%. However, three components were present (example 4), and the increase in type I collagen synthesis was 38.91%. The same experiment was performed using examples 1 to 3 and example 5 of the present invention, wherein the increase in synthesis of type I collagen was 37.25% in example 1, 39.13% in example 2, 38.50% in example 3, and 39.67% in example 5. The experiment proves that the three active components are compounded and have synergistic effect.
Experiment 3: human efficacy evaluation tests are shown in tables 5-7.
30 female subjects were selected, aged 25 to 50 years, with an average age of 35.6.+ -. 7.5 years. The subjects used the emulsion of example 7 once a day, both early and late, and a 14 day and 28 day visit, at the same time during the day, during which the same other type of product had not been used. Before testing, the subject sits still in a constant temperature and humidity waiting area with the temperature of 21+/-1 ℃ and the relative humidity of 50+/-10% RH for 20 minutes; the inspector collects the values of the skin elasticity parameter R2, the skin firmness parameter F4, and the values of Sa, sq, and SV of the skin in the cheek region of the subject.
Note that: p value < 0.001. Rate of change = (post-use measurement-pre-use measurement)/pre-use measurement 100%. The higher the rate of change, the higher the skin elasticity increase.
Table 5 shows: the skin elasticity changes before and after 28 days of application of the product. The value of the cheek region skin elasticity parameter R2 was significantly increased by 29.36% 28 days after the application of the product, compared to before the application of the product. The composition can significantly improve skin elasticity.
Table 6 skin firmness parameters F4 descriptive statistics (Cutometer MPA 580) (n=30)
Note that: p value < 0.001. Rate of change = (post-use measurement-pre-use measurement)/pre-use measurement 100%. For the value of the firmness parameter F4, the lower the value, the better the skin firmness is indicated.
Table 6 shows: changes in skin firmness around 28 days after application of the product. The cheek region skin firmness parameter F4 was reduced by a few 42.32% significantly 28 days after product use compared to before product use. Indicating that the composition can significantly improve skin firmness.
Table 7 descriptive statistics of skin wrinkles conditions (PRIMOS PICO) (n=30)
Test index | D0 (before using the product) | D28 (use product for 28 days) | Rate of change |
Sa | 26.3±4.6 | 20.5±4.3 | -22.05% |
Sq | 34.3±7.8 | 28.7±6.5 | -16.32% |
SV | -180.6±21.5 | -168.6±19.8 | 6.64% |
Note that: p value < 0.05.
As can be seen from table 7: after the subject used the emulsion containing the composition, the test showed that the Sa and Sq values decreased and the SV value increased over time. The composition is shown to be effective in improving skin wrinkling. According to the mechanism of wrinkle formation and the appearance of skin state, the skin elasticity, the compactness and the wrinkle condition can be combined with the anti-aging effect of the average product, and the combination of the test data shows that the skin care product containing the composition has obvious anti-aging effect.
The same human body efficacy evaluation test experiments are carried out by adopting the embodiment 6 and the embodiment 8 of the invention, and the skin care product disclosed by the embodiment 6 and the embodiment 8 can obviously improve the skin elasticity, the compactness and the obvious anti-aging effect.
The present invention is not limited to the above preferred embodiments, and any person skilled in the art, based on the technical solution of the present invention and the inventive concept thereof, can be replaced or changed within the scope of the present invention.
Claims (9)
1. An anti-aging composition is characterized by comprising the following components in parts by weight: 10 to 25 parts of bakuchiol, 30 to 50 parts of bidens pilosa extract and 30 to 65 parts of alfalfa extract.
2. An anti-aging composition according to claim 1, wherein the bakuchiol is 16-20 parts, the bidens pilosa extract is 35-45 parts, and the alfalfa extract is 40-50 parts.
3. Use of an anti-aging composition according to claim 1 in the preparation of a skin care product.
4. The use of an anti-aging composition according to claim 1 in the preparation of a skin care product, wherein the skin care product is a water agent, an emulsion, a cream, an essence, a facial mask or a gel, and the addition amount of the composition is 0.5-10% of the total mass of the skin care product.
5. The skin care product prepared from the anti-aging composition according to claim 1, which is characterized by comprising the anti-aging composition and an auxiliary agent, wherein the auxiliary agent is at least one of a chelating agent, a thickening agent, a humectant, a solubilizer, an emulsifier, a pH regulator, a preservative, a solvent, a skin feel improver, grease and essence.
6. The skin care product made of the anti-aging composition according to claim 5, wherein:
the chelating agent is disodium EDTA and/or tetrasodium EDTA;
the thickener is at least one of carbomer, sodium polyacrylate, xanthan gum, acrylic acid (ester) copolymer sodium, acrylamide dimethyl taurate/VP copolymer, acrylic acid (ester) C10-30 alkanol acrylate cross-linked polymer, polyacrylate cross-linked polymer-6 and acrylic acid hydroxyethyl acrylate/sodium acryl dimethyl taurate copolymer;
the humectant is at least one of glycerol, propylene glycol, butanediol, trehalose, dipropylene glycol, 1, 2-pentanediol, betaine and 1, 2-hexanediol;
the solubilizer is PEG-40 hydrogenated castor oil;
the emulsifier is at least one of cetostearyl oleate/sorbitan olive oleate, PEG-100 stearate, glyceryl stearate, lecithin, tween 60 and sodium stearyl glutamate;
the pH regulator is at least one of aminomethylpropanol, sodium hydroxide, arginine, citric acid, sodium citrate and tromethamine;
the preservative is at least one of phenoxyethanol, p-hydroxyacetophenone, potassium sorbate, sodium benzoate, octyl glycol and ethylhexyl glycerol;
the oil is at least one of squalane, BAIHUA oil, oleum Olivarum, caprylic/capric triglyceride, cetyl ethyl caproate, polydimethylsiloxane, and cetostearyl alcohol;
the skin feel improver is at least one of silica, corn starch and sodium starch octanoyl succinate;
the essence is daily essence;
the solvent is water.
7. The skin care product prepared from the anti-aging composition according to claim 5, wherein the skin care product is an anti-aging essence, and comprises phase A, phase B and phase C in percentage by weight;
phase A: 5% of glycerol, 0.8% of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 2% of dipropylene glycol, 0.5% of p-hydroxyacetophenone, 0.5% of 1, 2-hexanediol and the balance of water;
and B phase: 5% caprylic/capric triglyceride, 2% bakuchiol, 4% Bidens pilosa extract, 0.2% tween 60;
and C phase: 4% alfalfa extract;
the preparation method comprises the following steps: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, starting homogenizer, homogenizing at 5000-6000rpm for 4-6min; cooling to below 40deg.C, adding phase C, and stirring.
8. The skin care product prepared from the anti-aging composition according to claim 5, wherein the skin care product is an anti-aging emulsion and comprises the phase A, the phase B and the phase C in percentage by weight;
phase A: 5% of glycerol, 0.6% of polyacrylate crosslinked polymer-6, 5% of butanediol, 0.3% of sodium stearyl glutamate, 0.5% of p-hydroxyacetophenone, 0.5% of 1, 2-hexanediol and the balance of water;
and B phase: 6% cetyl ethyl hexanoate, 0.45% bakuchiol, 2% dimethicone, 1.8% Bidens pilosa extract, 1% PEG-100 stearate & glyceryl stearate;
and C phase: 0.75% alfalfa extract;
the preparation method comprises the following steps: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, starting homogenizer, homogenizing at 5000-6000rpm for 5-10min; cooling to below 40deg.C, adding phase C, and stirring.
9. The skin care product prepared from the anti-aging composition according to claim 5, wherein the skin care product is an anti-aging cream and comprises the phase A, the phase B and the phase C in percentage by weight;
phase A: 5% of glycerol, 0.5% of sodium polyacrylate, 5% of butanediol, 2% of betaine, 0.5% of p-hydroxyacetophenone, 0.5% of 1, 2-hexanediol and the balance of water;
and B phase: 3% cetyl ethylhexanoate, 3% cetostearyl alcohol, 3% squalane, 0.6% bakuchiol, 2% dimethicone, 0.4% bidens pilosa extract, 3% cetostearyl oleate/sorbitan olive oleate;
and C phase: 1% alfalfa extract;
the preparation method comprises the following steps: heating the phase A to 60-65 ℃, and stirring to be uniform; heating the phase B to 60-65 ℃, and stirring until the phase B is completely melted; adding phase B into phase A, starting homogenizer, homogenizing at 5000-6000rpm for 5-10min; cooling to below 40deg.C, adding phase C, and stirring.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310385567.4A CN116421517B (en) | 2023-04-12 | 2023-04-12 | Skin anti-aging composition and application and skin care product thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310385567.4A CN116421517B (en) | 2023-04-12 | 2023-04-12 | Skin anti-aging composition and application and skin care product thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116421517A CN116421517A (en) | 2023-07-14 |
CN116421517B true CN116421517B (en) | 2024-03-01 |
Family
ID=87090267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310385567.4A Active CN116421517B (en) | 2023-04-12 | 2023-04-12 | Skin anti-aging composition and application and skin care product thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116421517B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117205103A (en) * | 2023-10-07 | 2023-12-12 | 诺德溯源(广州)生物科技有限公司 | A firming and anti-aging composition containing plant A alcohol suitable for sensitive skin and its application |
CN118593400B (en) * | 2024-06-18 | 2025-03-04 | 广东丹兰国际生物科技有限公司 | Anti-wrinkle anti-aging composition containing traditional Chinese medicine components, and preparation method and application thereof |
CN119280095B (en) * | 2024-12-10 | 2025-03-21 | 广州源大生物科技有限公司 | Anti-wrinkle composition, use, skin care product, anti-wrinkle essence cream |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015167552A1 (en) * | 2014-04-30 | 2015-11-05 | Kimberly-Clark Worldwide, Inc. | Topical compositions including a bidens extract for reducing signs of skin aging |
CN105377230A (en) * | 2013-07-16 | 2016-03-02 | 宝洁公司 | Method of improving the appearance of aging skin |
CN107496316A (en) * | 2016-06-13 | 2017-12-22 | 欧诗漫生物股份有限公司 | A kind of face cream and preparation method thereof |
FR3067593A1 (en) * | 2017-06-20 | 2018-12-21 | Jean-Noel Thorel | USE OF PLANT EXTRACTS FOR THE DERMATOCOSMAL TREATMENT OF INFLAMMATORY CONDITIONS RELATED TO OVERPRODUCTION OF IL-17 |
CN112569130A (en) * | 2019-09-30 | 2021-03-30 | 珀莱雅化妆品股份有限公司 | Plant extract with pore tightening effect and preparation method thereof |
CN112618396A (en) * | 2021-01-04 | 2021-04-09 | 成都健腾生物技术有限公司 | A cosmetic prepared from bakuchiol |
CN113274331A (en) * | 2021-06-22 | 2021-08-20 | 科丝美诗(中国)化妆品有限公司 | Acne-removing and anti-inflammatory composition and preparation method and application thereof |
KR102370225B1 (en) * | 2021-10-15 | 2022-03-04 | 주식회사 엔에스엘 | Cream type cosmetic composition containing bakuchiol and preparing method thereof |
CN114478196A (en) * | 2021-01-27 | 2022-05-13 | 江苏巴帝恩生物科技有限公司 | Method for extracting and purifying bakuchiol from radix Ulmi Pumilae and its application in cosmetics |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9636292B2 (en) * | 2015-07-30 | 2017-05-02 | Truth Aesthetics LLC | Topical skin care composition for night use |
-
2023
- 2023-04-12 CN CN202310385567.4A patent/CN116421517B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105377230A (en) * | 2013-07-16 | 2016-03-02 | 宝洁公司 | Method of improving the appearance of aging skin |
WO2015167552A1 (en) * | 2014-04-30 | 2015-11-05 | Kimberly-Clark Worldwide, Inc. | Topical compositions including a bidens extract for reducing signs of skin aging |
CN107496316A (en) * | 2016-06-13 | 2017-12-22 | 欧诗漫生物股份有限公司 | A kind of face cream and preparation method thereof |
FR3067593A1 (en) * | 2017-06-20 | 2018-12-21 | Jean-Noel Thorel | USE OF PLANT EXTRACTS FOR THE DERMATOCOSMAL TREATMENT OF INFLAMMATORY CONDITIONS RELATED TO OVERPRODUCTION OF IL-17 |
CN112569130A (en) * | 2019-09-30 | 2021-03-30 | 珀莱雅化妆品股份有限公司 | Plant extract with pore tightening effect and preparation method thereof |
CN112618396A (en) * | 2021-01-04 | 2021-04-09 | 成都健腾生物技术有限公司 | A cosmetic prepared from bakuchiol |
CN114478196A (en) * | 2021-01-27 | 2022-05-13 | 江苏巴帝恩生物科技有限公司 | Method for extracting and purifying bakuchiol from radix Ulmi Pumilae and its application in cosmetics |
CN113274331A (en) * | 2021-06-22 | 2021-08-20 | 科丝美诗(中国)化妆品有限公司 | Acne-removing and anti-inflammatory composition and preparation method and application thereof |
KR102370225B1 (en) * | 2021-10-15 | 2022-03-04 | 주식회사 엔에스엘 | Cream type cosmetic composition containing bakuchiol and preparing method thereof |
Non-Patent Citations (3)
Title |
---|
"The Influence of Oligosaccharides on Skin Aging: An Alternative to Retinoids";Maud Jouandeaud等;《Cosmetics & Toiletries》;第119卷(第6期);第67-73页 * |
刘国良 等."补骨脂酚对光老化HSF细胞保护作用研究".《中国医药导报》.2019,第16卷(第19期),第11-15和24页. * |
孙成贤 等."三叶鬼针草乙醇提取物抗菌抗氧化活性研究".《安徽农学通报》.2021,第27卷(第11期),第32-35页. * |
Also Published As
Publication number | Publication date |
---|---|
CN116421517A (en) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116421517B (en) | Skin anti-aging composition and application and skin care product thereof | |
CN111249209B (en) | Moisturizing repair cream and preparation method thereof | |
AU707028B2 (en) | Use,in a composition, of an extract of at least one labiate | |
CN104887589B (en) | A kind of skin nursing skin cream and preparation method thereof | |
CN111450010A (en) | Composition with anti-aging effect and application thereof in cosmetics | |
CN110339149A (en) | A kind of facial treatment essence cream of the anti-ageing low sensitization of the whitening of the product containing lactobacillus fermentation | |
CN110302091B (en) | Composition containing nicotinamide adenine dinucleotide for resisting skin aging and preparation method and application thereof | |
CN111956591A (en) | Anti-allergy, soothing and skin color improving cosmetic composition and preparation method thereof | |
CN114712275A (en) | Anti-wrinkle repair composition and preparation method thereof, and cosmetic and preparation method thereof | |
CN112006958A (en) | Depilatory cream and preparation method thereof | |
CN112641692A (en) | Anti-allergy repairing composition and preparation method and application thereof | |
KR101130245B1 (en) | Composition formed by using mixture of herbal extracts and Muskrat Ondatra zibethicusmusk for Anti-aging | |
WO2024217163A1 (en) | Tricholoma matsutake extract-containing composition with anti-aging effect, and use thereof | |
CN114099388B (en) | Anti-wrinkle composition and preparation method and application thereof | |
KR101817514B1 (en) | New use of hesperetin | |
CN110693778A (en) | Face cream and production process thereof | |
CN104188859B (en) | A kind of crease-resistant skin care emulsion containing natural component extract and preparation method thereof | |
JP4906179B2 (en) | Topical skin preparation | |
CN117205103A (en) | A firming and anti-aging composition containing plant A alcohol suitable for sensitive skin and its application | |
KR20210090870A (en) | Cosmetic composition with excellent skin barrier using skin microbiome | |
CN117017850A (en) | External cosmetic composition for removing acne and repairing acne and application thereof | |
CN116407486A (en) | Active composition, cosmetic composition, application of active composition, repairing essence and preparation method of repairing essence | |
US11123386B2 (en) | Fermentation product of Punica granatum and uses thereof | |
CN109431881B (en) | Tibetan sheep oil for preventing skin from being cracked due to dryness | |
CN118340696B (en) | Mild anti-aging composition suitable for sensitive muscles and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |